Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Blennow, Ola  [Clear All Filters]
2024
Salmanton-García J, Marchesi F, Farina F, Weinbergerova B, Itri F, Dávila-Valls J, Martín-Pérez S, Glenthøj A, Hersby DStampe, da Silva MGomes, et al. Decoding the historical tale: COVID-19 impact on haematological malignancy patients-EPICOVIDEHA insights from 2020 to 2022. EClinicalMedicine. 2024;71:102553.
Aiello TFrancesco, Salmanton-García J, Marchesi F, Weinbergerova B, Glenthoj A, van Praet J, Farina F, Dávila-Valls J, Martín-Pérez S, El-Ashwah S, et al. Dexamethasone treatment for COVID-19 is related to increased mortality in hematologic malignancy patients: results from the EPICOVIDEHA Registry. Haematologica. 2024.
Müller TR, Gao Y, Wu J, Ribeiro O, Chen P, Bergman P, Blennow O, Hansson L, Mielke S, Nowak P, et al. Memory T cells effectively recognize the SARS-CoV-2 hypermutated BA.2.86 variant. Cell Host Microbe. 2024.
Lahmer T, Salmanton-García J, Marchesi F, El-Ashwah S, Nucci M, Besson C, Itri F, Jaksic O, Čolović N, Weinbergerova B, et al. Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey. Infection. 2024.
2023
Müller TR, Sekine T, Trubach D, Niessl J, Chen P, Bergman P, Blennow O, Hansson L, Mielke S, Nowak P, et al. Additive effects of booster mRNA vaccination and SARS-CoV-2 Omicron infection on T cell immunity across immunocompromised states. Sci Transl Med. 2023;15(704):eadg9452.
Salmanton-García J, Marchesi F, Koehler P, Weinbergerova B, Colović N, Falces-Romero I, Buquicchio C, Farina F, VAN Praet J, Biernat MM, et al. MOLNUPIRAVIR COMPARED TO NIRMATRELVIR/RITONAVIR FOR COVID-19 IN HIGH-RISK PATIENTS WITH HAEMATOLOGICAL MALIGNANCY IN EUROPE. A MATCHED-PAIRED ANALYSIS FROM THE EPICOVIDEHA REGISTRY. Int J Antimicrob Agents. 2023:106952.
El-Ashwah S, Salmanton-García J, Bilgin YM, Itri F, Žák P, Weinbergerova B, Verga L, Omrani AS, da Silva MGomes, Szotkowski T, et al. The mortality of COVID-19 in CML patients from 2020 until 2022: results from the EPICOVIDEHA survey. Leuk Lymphoma. 2023:1-10.
Chen P, Bergman P, Blennow O, Hansson L, Mielke S, Nowak P, Söderdahl G, Österborg A, Smith CIEdvard, Vesterbacka J, et al. Real-world assessment of immunogenicity in immunocompromised individuals following SARS-CoV-2 mRNA vaccination: a one-year follow-up of the prospective clinical trial COVAXID. EBioMedicine. 2023;94:104700.
Schain F, Boissin C, Laczik T, Fedeli S, Remberger M, Blennow O, Dykes J, Eich T, Jones C, Mattsson J, et al. Real-world clinical characterization, healthcare resource utilization and productivity loss in chronic graft versus host patients exposed to extracorporeal photopheresis in Sweden. Transfus Apher Sci. 2023:103705.
Musto P, Salmanton-García J, Sgherza N, Bergantim R, Farina F, Glenthøj A, Seval GCengiz, Weinbergerova B, Bonuomo V, Bilgin YM, et al. Survival in multiple myeloma and SARS-COV-2 infection through the COVID-19 pandemic: Results from the epicovideha registry. Hematol Oncol. 2023.
2022
Lamure S, Salmanton-García J, Marieton ERobin, Jaksic O, Kohn M, Marchesi F, Marchetti M, El-Ashwah S, Demirkan F, Valković T, et al. COVID-19 and Hairy-Cell Leukemia: An EPICOVIDEHA Survey. Blood Adv. 2022.
Gao Y, Cai C, Wullimann D, Niessl J, Rivera-Ballesteros O, Chen P, Lange J, Cuapio A, Blennow O, Hansson L, et al. Immunodeficiency syndromes differentially impact the functional profile of SARS-CoV-2-specific T cells elicited by mRNA vaccination. Immunity. 2022.
2015
Blennow O, Ljungman P. The challenge of antibiotic resistance in haematology patients. Br J Haematol. 2015.
2014
Blennow O, Fjaertoft G, Winiarski J, Ljungman P, Mattsson J, Remberger M. Varicella zoster reactivation after allogeneic stem cell transplantation without routine prophylaxis - the incidence remains high. Biol Blood Marrow Transplant. 2014.